#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Pearl Fang Email
VP, Clinical Development and Clinical Operations . Asceneuron
Lausanne,
LocationPrimary Email
How to contact Pearl Fang
Join and see Pearl's contact info for free!Current Roles
Employees:
21Revenue:
$3.3MAbout
Asceneuron is an emerging, clinical stage biotech company focusing on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need, such as orphan tauopathies, Alzheimer's and Parkinson's diseases. MISSION We strive to discover and develop truly effective therapeutics with the potential to radically improve the quality of life of patients with neurodegenerative diseases. To reach our ambitious goals, our team of experienced drug developers and scientists is working to the highest standards. Our decisions are driven by scientific excellence, patient-focus and integrity towards our stakeholders, with one ultimate goal: to deliver truly effective therapeutics for neurodegenerative diseases and transform the lives of patients suffering from orphan tauopathies, Alzheimer's and Parkinson's diseases. Our most advanced program has a particular focus on the orphan tauopathy Progressive Supranuclear Palsy (PSP). HISTORY Asceneuron was founded in 2012 through a spin-off of Merck Serono's Alzheimer's drug discovery portfolio and research group in Switzerland. We are a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners and Merck Ventures. Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer's Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation. PIPELINE Our lead product, SN120290, an O-GlcNAcase inhibitor, is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron has completed a randomized, double-blind, placebo-controlled phase I study to assess the safety and tolerability of single and multiple doses of orally administered ASN120290. Further information: www.asceneuron.comAsceneuron Address
EPFL Innovation ParkLausanne, null